A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
NCT06868485
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose Tumors harbor a C797S mutation within the Epidermal Growth Factor Receptor Gene.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Non Small Cell Lung Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Wayshine Biopharm, Inc.
- Last updated on ClinicalTrials.gov
- September 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- FOMAT Oncology · Oxnard, CA
Florida · 1
- Cleveland Clinic Weston Hospital · Weston, FL
Michigan · 1
- Karmanos Cancer Institute · Detroit, MI
New Jersey · 1
- Hackensack Meridian Health-Southern Ocean Medical Center · Manahawkin, NJ
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Pennsylvania · 1
- UPMC Hillman Cancer Center · Pittsburgh, PA
Texas · 1
- TxO Central/South, Texas Oncology -Central/South Texas · Austin, TX
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.